The Dermatology Department at St James’s hospital, has a long-established research program over the last 19 years. At all stages the research program is supported by the CRF. Our work centres on the most common inflammatory skin condition in adults, namely atopic dermatitis (eczema), and rare genetic skin disorders.

We run several investigator-led and industry centred drug trials for adults with eczema and for genetic skin disorders.

Our outlook is to continue to work on parallel mechanistic studies and early stage clinical trials, all with the aim of bringing better treatments to patients with debilitating skin diseases.

Current Trials & Studies
Study NameStudy TitleStudy TypeSponsorSponsor Type
A-STAR The UK-Irish Atopic Eczema Systemic TherApy Register Observational with radiology or blood tests British Association of Dermatologists Non-commercial: Academic
Measure Up 2 M18-891A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Stubjects with Moderate to Severe Atopic DermatitisClinical Trial (NCT03607422) (2018-001383-28)AbbvieSponsor
AD Up M16-047Moderate to Severe Atopic Dermatitis: Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult SubjectsClinical Trial (NCT03568318) (2017-005126-37) AbbvieIndustry Sponsored
Targ StaphTargeting staphylococci adhesion and colonization on the surface of corneocytes in Atopic Dermatitis Observational StudyLoreal SA Non-commercial: Academic
Past Trials & Studies
Study NameStudy TitleStudy TypeSponsorSponsor Type
ABT in Urticaria Health through attention based training (ABT) for patients in SJH with urticaria Observational-non invasive N/A Non-commercial: Academic
SERENALong term observational, prospective study to collect in a real life setting data on the retention, effectiveness, safety, treatment pattern, quality of life and efficiency of secukinumab in adult patients with moderate to severe plaque psoriasisNon-Interventional StudyNovartisIndustry Sponsored
Measure ADGlobal cross-sectional burden of illness study in adolescent and adult patients with atopic dermatitisNon-Interventional StudyAbbvieIndustry Sponsored
R668-AD-1424A Phase 3 Study Investigating the Efficacy, Safety, and Tolerability of Dupilumab Administered to Adult Patients with Severe Atopic Dermatitis who are not Adequately Controlled with or are Intolerant to Oral Cyclosporine A, or when this Treatment is not Medically AdvisableClinical trial (NCT02755649)RegeneronIndustry
R668-AD-1225 Open LabelAn open-label study of Dupilumab in Patients with Atopic Dermatitis who participated in previous Dupilumab Clinical TrialsClinical trial (NCT01949311) (2013-001449-15) RegeneronIndustry
Phase Dermatitis A Phase 3 study investigating the efficacy, safety and tolerability of dupilumab administered to adult patients with severe atopic dermatitis who are not adequately controlled with or are intolerant to oral cyclosporine A, or when this treatment is not medically advisable Clinical trial (NCT02755649) (2015-002653-35) Regeneron Pharmaceuticals Inc Industry
EASE Double-blind, Randomised, Vehicle-Controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow-up of Oleogel-S10 in patients with Inherited Epidermolysis Bullosa Clinical trial (NCT03068780) (2016-002066-32) Amryt Research Ltd Industry
Neutro ProThe role of neutrophil proteases as global regulators of IL-1 family cytokine activity in psoriasis Observational with radiology or blood tests SFINon-commercial: Academic
CAPS MCC950 and Derivatives in CAPs patients Observational with radiology or blood testsInflazome Ltd. Commercial: Industry
Ostoform Ostoform Patient Study Medical device study Ostoform Commercial: Industry